JP2010529152A - １７β−シアノ−１８ａ−ホモ−１９−ノル−アンドロスト−４−エン誘導体、その使用及び該誘導体を含む医薬 - Google Patents

１７β−シアノ−１８ａ−ホモ−１９−ノル−アンドロスト−４−エン誘導体、その使用及び該誘導体を含む医薬 Download PDF

Info

Publication number
JP2010529152A
JP2010529152A JP2010511525A JP2010511525A JP2010529152A JP 2010529152 A JP2010529152 A JP 2010529152A JP 2010511525 A JP2010511525 A JP 2010511525A JP 2010511525 A JP2010511525 A JP 2010511525A JP 2010529152 A JP2010529152 A JP 2010529152A
Authority
JP
Japan
Prior art keywords
homo
cyano
androst
methylene
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010511525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529152A5 (enExample
Inventor
クーンケ，ヨアヒム
フブナー，ヤン
ボールマン，ロルフ
フレンツェル，トーマス
クラール，ウルリッヒ
メンゲス，フレデリク
リンク，スフェン
ボルデン，シュテッフェン
ムーン，ハンス−ペーター
プレーレ，カトヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of JP2010529152A publication Critical patent/JP2010529152A/ja
Publication of JP2010529152A5 publication Critical patent/JP2010529152A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010511525A 2007-06-12 2008-06-04 １７β−シアノ−１８ａ−ホモ−１９−ノル−アンドロスト−４−エン誘導体、その使用及び該誘導体を含む医薬 Pending JP2010529152A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007027636A DE102007027636A1 (de) 2007-06-12 2007-06-12 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
PCT/EP2008/004428 WO2008151745A1 (de) 2007-06-12 2008-06-04 17beta-cyano-18a-homo-19-nor-androst-4-en-derivat, dessen verwendung und das derivat enthaltende arzneimittel

Publications (2)

Publication Number Publication Date
JP2010529152A true JP2010529152A (ja) 2010-08-26
JP2010529152A5 JP2010529152A5 (enExample) 2011-07-21

Family

ID=38858372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010511525A Pending JP2010529152A (ja) 2007-06-12 2008-06-04 １７β−シアノ−１８ａ−ホモ−１９−ノル−アンドロスト−４−エン誘導体、その使用及び該誘導体を含む医薬

Country Status (21)

Country Link
US (1) US20090048218A1 (enExample)
EP (1) EP2178899B1 (enExample)
JP (1) JP2010529152A (enExample)
KR (1) KR20100017780A (enExample)
CN (1) CN101679477A (enExample)
AR (1) AR066970A1 (enExample)
AU (1) AU2008261277A1 (enExample)
BR (1) BRPI0813455A2 (enExample)
CA (1) CA2689563A1 (enExample)
CL (1) CL2008001721A1 (enExample)
DE (1) DE102007027636A1 (enExample)
ES (1) ES2397879T3 (enExample)
IL (1) IL202300A0 (enExample)
MX (1) MX2009013626A (enExample)
PA (1) PA8784201A1 (enExample)
PE (1) PE20090312A1 (enExample)
RU (1) RU2010100334A (enExample)
TW (1) TW200906846A (enExample)
UY (1) UY31145A1 (enExample)
WO (1) WO2008151745A1 (enExample)
ZA (1) ZA201000185B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
SG10201706063UA (en) 2012-12-18 2017-09-28 Univ Washington Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169832A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
HRP20210610T1 (hr) * 2013-07-19 2021-05-28 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP4275748A3 (en) 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3885352B1 (en) 2014-10-16 2024-11-27 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
US3400136A (en) * 1965-06-21 1968-09-03 Smith Kline French Lab Method for preparing 6, 6-ethylene steroids
US3463776A (en) * 1965-09-23 1969-08-26 British Drug Houses Ltd Steroidal 6-cyclopropyl-4-en-3-ones and process for preparing same
US3705179A (en) * 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
JPS5647200B1 (enExample) * 1971-06-01 1981-11-07
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1183500B (de) 1962-10-12 1964-12-17 Schering Ag Verfahren zur Herstellung von alpha, beta-Methylenketonen der Steroidreihe
IL32699A (en) * 1968-07-30 1973-06-29 American Home Prod 6-substituted-13-polycarbonalkyl-18,19 dinorpregn-4-en-3-ones,their preparation and pharmaceutical compositions containing them
FR2081561B1 (enExample) * 1970-03-03 1973-04-06 Roussel Uclaf
US3994937A (en) * 1972-02-11 1976-11-30 Schering Aktiengesellschaft 15α,16α-Methylene-4-estren-17β-ols
BE795241A (fr) 1972-02-11 1973-08-09 Schering Ag 15alpha, 16alpha-methylene-4-oestren-17beta-ols-methylenz-4-oestren-17beta-ols et leur procede de preparation
NL7701384A (nl) * 1977-02-10 1978-08-14 Akzo Nv Werkwijze voor het bereiden van nieuwe steroiden van de oestraanreeks.
DE2922500A1 (de) 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
US4252800A (en) * 1979-10-05 1981-02-24 United States Of America 7α-methylnorethindrone enanthate and its use in long term suppression of fertility in female mammals
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DE3402329A1 (de) 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043833A (en) * 1961-07-14 1962-07-10 Ormonoterapia Richter Spa 17-cyanohydrin of 19-nor androstenedione and 3-derivatives thereof
US3400136A (en) * 1965-06-21 1968-09-03 Smith Kline French Lab Method for preparing 6, 6-ethylene steroids
US3463776A (en) * 1965-09-23 1969-08-26 British Drug Houses Ltd Steroidal 6-cyclopropyl-4-en-3-ones and process for preparing same
US3705179A (en) * 1971-03-15 1972-12-05 American Home Prod Antiandrogenic steroids
JPS5647200B1 (enExample) * 1971-06-01 1981-11-07
EP0785211A1 (en) * 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013013419; ＷＩＬＫＳ，Ｊ．Ｍ．　ｅｔ　ａｌ．: 'Ｓｔｅｒｏｉｄ　ｂｉｎｄｉｎｇ　ｓｐｅｃｉｆｉｃｉｔｙ　ｏｆ　ｔｈｅ　ｈａｍｓｔｅｒ　ｕｔｅｒｉｎｅ　ｐｒｏｇｅｓｔｅｒｏｎｅ　ｒｅｃｅｐｔｏｒ' ＳＴＥＲＯＩＤＳ Ｖｏｌ．３５，　Ｎｏ．６, 1980, ｐ．６９７-７０６ *
JPN6013013420; ＤＥ　ＧＯＯＹＥＲ，Ｍ．Ｅ．　ｅｔ　ａｌ．: 'Ｒｅｃｅｐｔｏｒ　ｐｒｏｆｉｌｉｎｇ　ａｎｄ　ｅｎｄｏｃｒｉｎｅ　ｉｎｔｅｒａｃｔｉｏｎｓ　ｏｆ　ｔｉｂｏｌｏｎｅ' ＳＴＥＲＯＩＤＳ Ｖｏｌ．６８，　Ｎｏ．１, 2003, ｐ．２１-３０ *
JPN6013013421; ＤＯＲＥ，Ｊ．Ｃ．　ｅｔ　ａｌ．: 'Ｃｏｒｒｅｓｐｏｎｄａｎｃｅ　Ａｎａｌｙｓｉｓ　Ａｐｐｌｉｅｄ　ｔｏ　Ｓｔｅｒｏｉｄ　Ｒｅｃｅｐｔｏｒ　Ｂｉｎｄｉｎｇ' Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．２９，　Ｎｏ．１, 1986, ｐ．５４-６０ *
JPN6013013422; ＳＡＬＭＡＮ，Ｍ．　ｅｔ　ａｌ．: 'Ａ　ＰＯＴＥＮＴＩＡＬ　ＲＡＤＩＯＩＯＤＩＮＡＴＥＤ　ＬＩＧＡＮＤ　ＦＯＲ　ＡＮＤＲＯＧＥＮ　ＲＥＣＥＰＴＯＲ　７-ＡＬＰＨＡ　ＭＥＴＨＹＬ-１７-ＡＬＰＨＡ-２'-Ｅ-ＩＯＤＯＶＩＮＹＬ-１９-ＮＯ' Ｊ．　Ｍｅｄ．　Ｃｈｅｍ． Ｖｏｌ．３４，　Ｎｏ．３, 1991, ｐ．１０１９-２４ *

Also Published As

Publication number Publication date
ES2397879T3 (es) 2013-03-12
IL202300A0 (en) 2010-06-30
EP2178899A1 (de) 2010-04-28
US20090048218A1 (en) 2009-02-19
BRPI0813455A2 (pt) 2014-12-23
PA8784201A1 (es) 2009-01-23
EP2178899B1 (de) 2012-10-24
CA2689563A1 (en) 2008-12-18
UY31145A1 (es) 2009-01-30
PE20090312A1 (es) 2009-04-09
RU2010100334A (ru) 2011-07-20
KR20100017780A (ko) 2010-02-16
ZA201000185B (en) 2011-03-30
AU2008261277A1 (en) 2008-12-18
AR066970A1 (es) 2009-09-23
TW200906846A (en) 2009-02-16
CL2008001721A1 (es) 2008-12-19
WO2008151745A1 (de) 2008-12-18
DE102007027636A1 (de) 2008-12-18
CN101679477A (zh) 2010-03-24
MX2009013626A (es) 2010-01-20

Similar Documents

Publication Publication Date Title
JP2010529152A (ja) １７β−シアノ−１８ａ−ホモ−１９−ノル−アンドロスト−４−エン誘導体、その使用及び該誘導体を含む医薬
KR101440640B1 (ko) 18-메틸-19-노르안드로스트-4-엔-17,17-스피로에테르 (18-메틸-19-노르-20-스피록스-4-엔-3-온), 및 이를 함유하는 제약 제제
JP5043681B2 (ja) １８−メチル−１９−ノル−１７−プレグン−４−エン−２１，１７−カルボラクトンおよびこれを含有する製剤
US8207150B2 (en) 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative
AU2008266526A1 (en) Substituted (oxazolidinon-5-yl-methyl) -2-thiophene-carboxamides and use thereof in the field of blood coagulation
US20100292184A1 (en) 17beta-cyano-19-androst-4-ene derivative, its use and medicaments comprising the derivative
CN101910192B (zh) 具有15α,16α-亚甲基和饱和的17,17-螺内酯环的19-去甲甾类衍生物、其应用以及包含这些衍生物的药物
JP5600068B2 (ja) １７−ヒドロキシ−１９−ノル−２１−カルボン酸−ステロイドγ−ラクトン誘導体、それらの使用および前記誘導体を含有する医療製品
JP5600069B2 (ja) １７−（１’−プロペニル）−１７−３’−オキシドエストラ−４−エン−３−オン誘導体、その使用及び当該誘導体を含む医薬品
HK1141536A (en) 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative
HK1141535A (en) 17β-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE
HK1141537A (en) 17β-CYANO-19-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE
TW201029656A (en) Use of 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-18a-homo-19-nor-androst-4-ene derivatives for parenteral administration
TW201026719A (en) Use of 17β-cyano-19-nor-androst-4-ene derivatives for preparing a medicament in depot form for parenteral administration and depot medicaments comprising 17β-cyano-19-nor-androst-4-ene derivatives for parenteral administration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130626

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140311